Adenosine Receptor A1-A2a Heteromers Regulate EAAT2 Expression and Glutamate Uptake via YY1-Induced Repression of PPARγ Transcription

Xianhua Hou, Yuan Li, Yuanyuan Huang, Huan Zhao, and Li Gui

Department of Neurology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China

Correspondence should be addressed to Li Gui; 1695509991@qq.com

Received 12 October 2019; Accepted 23 January 2020; Published 6 March 2020

Academic Editor: Paul D. Drew

Copyright © 2020 Xianhua Hou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Adenosine receptors A1 (A1AR) and A2a (A2aAR) play an important role in regulating glutamate uptake to avoid glutamate accumulation that causes excitotoxicity in the brain; however, the precise mechanism of the effects of A1AR and A2aAR is unclear. Herein, we report that expression of the A1AR protein in the astrocyte membrane and the level of intracellular glutamate were decreased, while expression of the A2aR protein was elevated in cells exposed to oxygen-glucose deprivation (OGD) conditions. Coimmunoprecipitation (Co-IP) experiments showed that A1AR interacts with A2aAR under OGD conditions. The activation of A1AR and inactivation of A2aAR by 2-chloro-N6-cyclopentyladenosine (CCPA) and SCH58251, respectively, partly reversed OGD-mediated glutamate uptake dysfunction, elevated EAAT2, and PPARγ protein levels, and suppressed the expression of Ying Yang 1 (YY1). Both the silencing of YY1 and the activation of PPARγ upregulated EAAT2 expression. Moreover, YY1 silencing elevated the PPARγ level under both normal and OGD conditions. Histone deacetylase (HDAC)1 was found to interact with YY1, and HDAC1 silencing improved PPARγ promoter activity. Taken together, our findings suggest that A1AR-A2aAR heteromers regulate EAAT2 expression and glutamate uptake through the YY1-mediated recruitment of HDAC1 to the PPARγ promoter region.

1. Introduction

Ischemic stroke, the most common subtype of stroke, seriously threatens public health in China, with up to 2.5 million new stroke cases reported every year and high rates of mortality [1, 2]. The exposure of astrocytes to oxygen-glucose deprivation (OGD) conditions induces dysfunction of glutamate clearance and inflammatory mediator release, resulting in excitotoxic neuronal death during the ischemic process [3–7]. Therefore, astrocytes, the most abundant glial cell type, play a crucial role in the pathological process of ischemic stroke [8], and the restoration of glutamate clearance function in astrocytes is a therapeutic approach for neuroprotection in ischemic stroke [9].

The role of rapid extracellular glutamate clearance in astrocytes is dependent on excitatory amino acid transporters (EAATs), also known as glutamate transporters (GluTs) [10, 11]. The EAAT family contains five subtypes: EAAT1, EAAT2, EAAT3, EAAT4, and EAAT5 [12]. Studies have revealed that EAAT1 and EAAT2 are predominantly expressed in astrocytes and that EAAT3, EAAT4, and EAAT5 are located in neurons [13, 14]. In particular, EAAT2, the most abundant GluT in the brain [15], plays a major role in the uptake of extracellular glutamate [16–18]. Several studies have reported that the expression of EAAT2 is suppressed in brain tissue suffering from neurological disorders, including ischemia, manganism, and Alzheimer’s disease (AD) [10]. Further studies reported that EAAT2/GLT1 expression is regulated at the transcriptional and translational levels through a complex mechanism that involves factors such as PI3K-Akt [19], NF-κB [20], and the epigenetic modifiers histone deacetylase (HDAC) I and II [21]. However, the mechanism of EAAT2 regulation has not been fully clarified.
Adenosine receptor (AR), a member of the G protein-coupled receptor (GPCR) superfamily, consists of four AR subtypes: adenosine receptor A1 (A1AR), adenosine receptor A2a (A2aAR), A2bAR, and A3AR [22]. In particular, A1AR and A2aAR are highly expressed throughout brain tissue and have a high affinity for adenosine [23, 24]. Adenosine binds A1AR and A2aAR and then initiates several biological processes, such as the regulation of glutamate release [25, 26]. Researchers found that A1AR and A2aAR are coexpressed at 61% of presynaptic terminals from cortical glutamatergic neurons in the striatum, caudate nucleus, and hippocampus [27, 28]. Recently, Cristovao-Ferreira et al. demonstrated that A1AR and A2aAR colocalized at the cell surface [28–30]. Further study showed that A1AR could interact with A2aAR to form A1AR-A2aAR heteromers. The activation of A2aAR can uniquely inhibit the A1AR-mediated biological response [31]. In ischemic stroke, the activation of A2aAR by a high concentration of adenosine elevates the intracellular glutamate level and exacerbates neuronal injury [32, 33], whereas adenosine- or pharmaceutical agonist-induced activation of A1AR has been shown to play a protective role under ischemia [34, 35]; A1AR activation reduced glutamate release and promoted ischemic tolerance [36, 37]. However, whether A1AR closely interacts with A2aAR to form A1AR-A2aAR heteromers and the role of A1AR-A2aAR heteromers in ischemic stroke are largely unknown.

Given that a major function of astrocytes in the regulation of glutamate clearance, the first aim of the present work was to clarify whether OGD induces A1AR-A2aAR heteromer formation and modulates glutamate uptake in astrocytes. In addition, we explored the novel mechanism by which A1AR-A2aAR heteromers regulate EAAT2 expression and glutamate uptake in astrocytes.

2. Method and Materials

2.1. Materials and Reagents. DMEM (with high glucose or no glucose), Opti-MEM™-reduced serum medium (Opti-MEM), fetal bovine serum (FBS), and trypsin-EDTA (0.25%) were obtained from Gibco (Shanghai, China). Anti-A1AR antibody, A2aAR, GFAP, S100β, anti-PPARγ antibody, a glutamate assay kit, and 2-chloro-N6-cyclopentyladenosine (CCPA) were purchased from Abcam, Inc. (Shanghai, China). Anti-β-tubulin antibody, anti-α/β-tubulin antibody, anti-β-actin antibody, and anti-Ying Yang 1 (YY1) antibody were purchased from Cell Signaling Technology, Inc. Protein A/G Plus agarose was purchased from Santa Cruz Biotechnology, Inc. (Shanghai, China). CCPA, SCH58261, and CGS21680 were purchased from Selleck, Inc. (Shanghai, China). HRP-goat anti-rabbit IgG (H+L), HRP-goat anti-mouse IgG (H+L), Alexa Fluor® 488-goat anti-rabbit IgG (H+L), and Alexa Fluor® 594-goat anti-rabbit IgG (H+L) were ordered from Jackson Immunoresearch, Inc. (Philadelphia, USA). GoTaq® qPCR Master Mix, a Luciferase Reporter Gene Assay Kit, GoScript™ RT Mix, and FuGENE® HD Transfection Reagent were purchased from Promega Biotech Co., Ltd. (Beijing, China). T-PER™ Tissue Protein Extraction Reagent and the Mem-PER™ Plus Kit were purchased from Thermo Fisher Co., Ltd. (Shanghai, China). Immobilon Western Chemiluminescence HRP Substrate (ECL kit) was purchased from Merck Millipore Co., Ltd. (Shanghai, China). Polyvinylidene fluoride (PVDF) membranes were purchased from GE Co., Ltd. (Germany). TRIzol reagent and other reagents were purchased and used as received from Sigma-Aldrich (Shanghai, China). The details of materials and reagents are shown in the supplement file (available here).

2.2. Mouse Primary Astrocyte Culture and OGD Treatment. Primary cortical astrocytes were isolated and cultured according to a previous report [38]. Briefly, mouse pups were sacrificed by decapitation using scissors. Cortical hemispheres were isolated with fine forceps and then cut into small pieces for trypsinization in a water bath at 37°C for 30 min. Cortex tissue pieces were dissociated into a single-cell suspension and cultured in culture flasks. After culture for 7–8 days, microglia and oligodendrocyte precursor cells were removed by shaking. Astrocytes were used for further study after their culture for an additional 6 days.

For OGD treatment, the culture medium was removed, and astrocytes were washed twice with PBS. Glucose-free DMEM was added to the culture flask, and the astrocytes were exposed to 1% O2 for 6 h.

2.3. Immunofluorescence Assay. Primary astrocytes were fixed with 4% formaldehyde for 15 min and washed with PBS. These samples were blocked with 5% normal goat serum for 1 h at RT and incubated with anti-GFAP or anti-S100B antibody overnight at 4°C. After being washed three times with PBS, the samples were incubated with Alexa Fluor® 488-goat anti-rabbit IgG (H+L) or Alexa Fluor® 594-goat anti-rabbit IgG (H+L) for 1 h at RT. The nuclei were stained with diamidino-phenylindole (DAPI).

2.4. Coimmunoprecipitation (Co-IP) and Western Blotting. Co-IP and western blotting were performed according to a previous study [39]. Briefly, the treated cells were harvested and then centrifuged at 14,000 × g and 4°C for 15 min. The supernatants were then transferred into new tubes and incubated with anti-A1AR antibody (1:50) or anti-YY1 antibody (1:50) overnight with protein A/G agarose beads for 2 h at 4°C. The solutions were then evaluated by western blotting.

2.5. Glutamate Uptake Assay. For the glutamate uptake assay, the treated astrocyte medium was discarded, and the cells were washed with D-Hank’s solution. The cells were preincubated with 300 nM glutamate for 7 min, and glutamate uptake was terminated with ice-cold Hank’s solution, followed by immediate analysis using a glutamate assay kit [40, 41]. The level of intracellular glutamate was analyzed using a glutamate assay kit (colorimetric) according to the manufacturer’s instructions. Briefly, the treated cells and medium were collected, and the cells were resuspended in assay buffer. These samples were incubated for 30 min on ice and centrifuged for 5 min at 4°C. The supernatant was collected, and the reaction mixture was added and incubated with the samples. The absorbance values of the samples were measured at 450 nm.
2.6. EYFP-A1AR Plasmid, A2aAR siRNA, YY1 siRNA, and HDAC1 siRNA Transfection. pcDNA3.1/opto-a1AR-EYFP was a gift from Karl Deisseroth (Addgene plasmid #20947). A2aAR and YY1 siRNA were purchased from GenePharma (Shanghai, China). The sequence of A2aAR siRNA was 5′-AAACTTCTTCGTGGTATCTCT-3′ [42]. The sequence of YY1 siRNA was 5′-TTGTTCAATGTAGTCGTCG-3′, and the HDAC1 siRNA sequence was 5′-GTTGGAAGA GTTCTTCGGG-3′. Astrocytes were cultured on 6-well dishes, and 2 μg of plasmid or 200 nM siRNA was used to transfect the astrocytes using FuGENE® HD transfection reagent for 48 h. Treated cells were used for further study.

2.7. Luciferase Assay. The promoter region of PPARγ was synthesized and inserted into the pXPG plasmid, which was a gift from Peter Cockerill (Addgene plasmid #71248). This plasmid and a pRL Renilla luciferase control reporter vector were cotransfected into 293 T cells. Luciferase assays were carried out according to the manufacturer’s protocol.

2.8. Statistical Analysis. The data from at least three independent experiments are expressed as the mean ± standard error (S.E.). One-way analysis of variance (ANOVA) and Student’s t-test were carried out. p < 0.05 indicated statistically significant differences.

3. Results

3.1. OGD Regulated A1AR and A2aAR Expressions. Astrocytes play an important role in taking up excess glutamate to avoid excitotoxicity to neurons [11]. Herein, we isolated and cultured mouse primary cortical astrocytes (Figure 1(a)). Immunostaining showed that S100B and GFAP, which are astrocyte markers, were strongly expressed in the cytoplasm of these cells (Figure 1(b)). OGD can be used to develop an in vitro
model of brain ischemia. In our study, astrocytes were under OGD for 1 h and 6 h. Western blotting showed that the expression of A1AR on the cell surface was decreased after OGD treatment, whereas A2aAR protein levels were elevated. Furthermore, expression of the EAAT2 protein was also decreased after cells exposed to OGD (Figure 1(c)). Interestingly, the Co-IP assay showed that OGD promoted the interaction between A1AR and A2aAR (Figure 1(d)). Additionally, the intracellular glutamate level was significantly decreased after cells were subjected to OGD for 1 and 6 h compared to 0 h (p < 0.05) (Figure 1(e)). These data suggest that A1AR interacts with A2aAR to form an A1AR-A2aAR heterodimer involved in the regulation of EAAT2 expression and glutamate uptake.

3.2. A1AR and A2aAR Regulated the Expression of EAAT2 and Glutamate Uptake. We explored the role of A1AR and A2aAR in the regulation of EAAT2 and glutamate uptake. The activation of A1AR with CCPA and the inactivation of A2aAR with SCH58261 elevated EAAT2 protein levels in astrocytes under OGD conditions (Figure 2(a)). Similarly, compared to those in the group under OGD alone, intracellular glutamate levels were increased in the OGD/CCPA, OGD/SCH58261, and OGD/CCPA+SCH58261 groups (p < 0.05). Interestingly, the level of glutamate was higher in the OGD/CCPA+SCH58261 group than that in the OGD/CCPA group (p < 0.05) (Figure 2(b)). Furthermore, the expression of EAAT2 and the level of glutamate were not significantly increased in the OGD/CCPA+SCH58261 group compared to the group under OGD alone (p > 0.05) (Figures 2(c) and 2(d)). These data indicate that A1AR activation and A2aAR inactivation can elevate the expression of EAAT2 and improve glutamate uptake in astrocytes under OGD conditions. To further confirm the role of A1AR and A2aAR in the regulation of EAAT2 expression, A2aAR was knocked down with A2aAR siRNA (Figure 2(e)). The levels of EAAT2 protein and intracellular glutamate were increased in A2aAR-silenced cells under OGD compared to cells were under OGD alone (p < 0.05) (Figures 2(f) and 2(g)). Similarly, the forced expression of A1AR by the EYFP-A1AR plasmid partly reversed the OGD-mediated downregulation of EAAT2 expression and impaired glutamate uptake (Figures 2(h)–2(j)). These data suggested that A2aAR interacts with A1AR and forms an A1AR/A2aAR heterodimer, resulting in the suppressive activity of A1AR and glutamate uptake through the inhibition of EAAT2 expression.

3.3. PPARγ Regulated Glutamate Uptake by EAAT2. We then evaluated whether PPARγ regulates the expression of EAAT2 and glutamate uptake. Astrocytes were pretreated with rosiglitazone (RSG), a PPARγ agonist and subjected to OGD. PPARγ activation increased the expression of EAAT2 and the intracellular glutamate level compared to those in the group under OGD alone (Figures 3(a) and 3(b)). These data suggested that PPARγ can promote the expression of EAAT2 and attenuate OGD-impaired glutamate uptake. We further studied whether the A1AR/A2aAR heterodimer regulates PPARγ expression. Figure 3(c) shows that the expression of PPARγ increased when astrocytes were preincubated with CCPA and SCH58261 and then treated with OGD compared to astrocytes treated with OGD alone. A2aAR silencing elevated the level of PPARγ in cultures under OGD in the absence or presence of CCPA (Figure 3(d)). Additionally, GW9962, an inhibitor of PPARγ, abrogated the CCPA- and SCH58261-induced increase in EAAT2 expression under OGD conditions (Figures 3(e) and 3(f)). These results suggest that the A1AR/A2aAR heterodimer regulates EAAT2 levels through PPARγ.

3.4. The A1AR/A2aAR Heterodimer Regulated the Expression of YY1. In this study, we found that expression of the YY1 protein, a transcription factor, was increased (Figure 4(a)) after astrocytes were placed under OGD conditions. Further study showed that the expression of YY1 decreased when astrocytes were preincubated with CCPA and SCH58261 and then placed under OGD conditions compared to OGD alone (Figure 4(b)). Moreover, the expression of YY1 in A2aAR-silenced cultures under OGD in the absence or presence of CCPA was attenuated (Figure 4(c)). These data suggested that the A1AR/A2aAR heterodimer regulates YY1 expression. Figure 4(d) shows that YY1 siRNA knocked down YY1 protein levels. YY1 silencing promoted the expression of EAAT2 in cells under both normal and OGD conditions (Figure 4(e)). The glutamate uptake assay showed that YY1 silencing increased intracellular glutamate levels in cells under OGD conditions (Figure 4(f)), suggesting that YY1 silencing can attenuate OGD-impaired glutamate uptake.

3.5. HDAC1 Recruitment by YY1 Repressed PPARγ. The above results revealed that YY1 and PPARγ can regulate the expression of EAAT2; however, the relationship between YY1 and PPARγ is unknown. We found that YY1 silencing elevated the level of PPARγ in cells under both normal and OGD conditions (Figure 5(a)). Moreover, the expression of HDAC1 was increased after OGD challenge (Figure 5(b)). Further study showed that OGD promoted the interaction between YY1 and HDAC1 (Figure 5(c)), suggesting that YY1 can recruit HDAC1 under OGD conditions. A luciferase assay showed that HDAC1 silencing significantly promoted PPARγ promoter activity (Figures 5(d) and 5(e)). These data suggest that YY1 recruits HDAC1 to inhibit PPARγ promoter activity under OGD conditions, resulting in the repression of EAAT2 expression and glutamate uptake in astrocytes.

4. Discussion

Stress induced the formation of homo-oligomeric and hetero-oligomeric GPCR complexes and it might interrupt the function of A1AR or A2aAR [31]. Herein, we found that OGD promoted the formation of A1AR-A2aAR heteromers and the activation of A1AR or inactivation of A2aAR attenuated OGD-mediated EAAT2 inhibition and glutamate uptake dysfunction. PPARγ could regulate EAAT2-mediated glutamate uptake [43]. Therefore, we investigated whether A1AR/A2aAR heteromers regulated EAAT2 through PPARγ. These data revealed that A1AR/A2aAR heterodimer by activation of A1AR or inactivation of A2aAR attenuated OGD-mediated suppress PPARγ suppression, resulting in elevating the level of intracellular glutamate. Next, we further study
the mechanism of A1AR-A2aAR heteromers to control EAAT2 via PPARγ. Given YY1 could repress the expression of EAAT2 [21] and was a transcription factor for regulation of EAAT2 via PPARγ [44], we carried out experiments and revealed that YY1 suppressed the expression of EAAT2 through the recruitment of HDAC1 to the PPARγ promoter region. These data suggested A1AR-A2aAR heterodimerization regulation of EAAT2 expression and glutamate uptake through YY1-induced recruitment of HDAC1 to the PPARγ promoter region.

GPCRs, such as A1AR and A2aAR, detect and transmit extracellular chemicals into cells and activate downstream signals, resulting in the initiation of physiological and pathological responses [45]. In general, GPCRs are monomeric...
receptors that are present and function at the cell surface [46]. However, recent studies revealed the presence of homo-oligomeric and hetero-oligomeric GPCR complexes at the surface of cultured cells [47, 48]. These homo/heterodimers might be regulated in various ways, such as through agonists/antagonists. In particular, the functions of GPCR heterodimers, including their pharmacological properties and activation, may be significantly different than those of GPCR monomers [49, 50]. Several studies showed that A2aAR and A1AR interact and heterodimerize in hippocampal and cortical synaptosomes [28, 29, 51]. Additionally, A2aAR in this heterodimer can decrease the affinity of A1AR for its agonist [28]. In the present study, OGD promoted the interaction of A1AR with A2aAR in astrocytes and suppressed the expression of EAAT2 and glutamate uptake. A previous study showed that the activation of A2aAR also impaired glutamate clearance [33] and that the activation of A1AR played a protective role in ischemia [34, 35, 52]. Therefore, we suspected that OGD induces A1AR-A2aAR heterodimerization and that A2aAR activation suppresses A1AR-mediated regulation of EAAT2 expression. Further study demonstrated that both A1AR activation and A2aAR inactivation improved the OGD-mediated decrease in EAAT2 protein levels and damage to glutamate uptake. Interestingly, A2aAR agonist preconditioning blocked A1AR activation-induced changes in EAAT2 expression and glutamate uptake. These data prove that OGD mediates A1AR-A2aAR heterodimerization and suppresses the activity of A1AR, resulting in impaired glutamate uptake through the inhibition of EAAT2 expression.

PPARγ, a member of the nuclear receptor superfamily of ligand-activated transcription factors, regulates gene transcription by binding peroxisome proliferator response elements (PPREs) in the promoter regions of target genes [53]. Activation of PPARγ plays a critical role in immunity, inflammation [54], and metabolism [55]. Recently, Tureyen et al. showed that the activation of PPARγ by RSG suppressed the inflammatory response and decreased the infarct volume and neurological deficits in middle cerebral artery occlusion (MCAO) model rats [56]. Ching and colleagues showed that the levels of extracellular glutamate were controlled by PPARγ activity in both U87MG and U251MG cells [57]. Another study demonstrated that PPARγ has a neuroprotective effect by upregulating EAAT2 promoter activity in astrocytes [43]. Consistent with previous reports, PPARγ was able to promote the expression of EAAT2 and attenuate OGD-impaired glutamate uptake. We found that the activation of A1AR and the inactivation of A2aAR could increase the level of PPARγ in astrocytes exposed to OGD conditions. These data suggested that A1AR/A2aAR heteromers control EAAT2 levels and glutamate uptake through regulating PPARγ expression.

Figure 3: PPARγ regulated the expression of EAAT2 and glutamate release from astrocytes. (a, b) EAAT2 protein and intracellular glutamate levels in astrocytes under OGD in the absence or presence of 1 μM rosiglitazone were detected by western blotting or with a glutamate assay kit, respectively. The data represent the means ± S.E. (n = 3). *p < 0.05 vs. the control group and †p < 0.05 vs. the OGD group. (c) Western blot analysis of the expression of PPARγ in astrocytes treated with 30 nM CCPA and 200 nM SCH58261 that were exposed to OGD for 6 h. D. The PPARγ protein level in astrocytes transfected with A2aAR siRNA for 48 h before being subjected to OGD conditions with 30 nM CCPA was evaluated. (e, f) Western blot analysis of the expression of EAAT2 in astrocytes treated with 30 nM CCPA or 200 nM SCH58261 in the presence of 30 μM GW9662, followed by exposure to OGD for 6 h.
Figure 4: The A1AR/A2aAR heterodimer regulated EAAT2 expression via YY1. (a) The YY1 protein level in astrocytes under OGD conditions for 1 h and 6 h was evaluated. (b) Western blot analysis of YY1 expression in cells treated with 30 nM CCPA and 200 nM SCH58261 that were exposed to OGD for 6 h. (c) The YY1 protein level in astrocytes transfected with A2aAR siRNA for 48 h, followed by exposure to OGD conditions with 30 nM CCPA, was evaluated. The expression of PPARγ and YY1 in treated astrocytes was evaluated by western blotting. (d) The YY1 protein after the transfection of YY1 siRNA into astrocytes for 48 h was evaluated by western blotting. YY1-silenced astrocytes were subjected to OGD conditions in the absence or presence of 30 nM CCPA. (e, f) The expression of YY1 and EAAT2 and the intracellular glutamate level were detected by western blotting or with a glutamate assay kit, respectively. The data represent the means ± S.E. (n = 3). *p < 0.05 vs. the NC group and ^p < 0.05 vs. the OGD/NC group.

Figure 5: YY1 regulated PPARγ by HDAC1. (a) The PPARγ protein level in astrocytes transfected with YY1 siRNA for 48 h and then exposed to OGD for 6 h was evaluated. (b) The protein level of HDAC1 in astrocytes exposed to OGD for 6 h was measured. (c). Co-IP assays were used to evaluate the interaction between YY1 and HDAC1. (d) The protein level of HDAC1 in astrocytes transfected with HDAC1 siRNA for 48 h was evaluated by western blotting. (e) Luciferase assays evaluated the PPARγ promoter activity in 293 T cells transfected with HDAC siRNA for 48 h and then exposed to OGD for 6 h. The data represent as the means ± S.E. (n = 3). *p < 0.05 vs. the NC group and ^p < 0.05 vs. the NC/OGD group.
YY1, a transcription factor, regulates multiple proteins involved in cell proliferation and differentiation, apoptosis, and chromatin remodeling in various cell types [58–63]. Recent research has revealed that YY1 plays a critical role in neural development, neuronal function, developmental myelination, and neurological diseases [64]. Aguirre et al. and Rosas et al. found that YY1 represses GluT (GLAST)/EAAT1 expression through binding its promoter in chick glial cells [65, 66]. Further study also demonstrated that YY1 negatively regulates EAAT1 and EAAT2 expression in rat astrocytes [21, 67]. Consistent with the above documents, in our study, OGD induced YY1 expression, and YY1 silencing elevated EAAT2 protein levels and attenuated OGD-impaired glutamate uptake in mice astrocytes. Interestingly, the expression of YY1 was suppressed through the activation of A1AR or the inactivation of A2aAR. These data suggested that YY1 recruited HDAC1 to inhibit PPARγ promoter activity under OGD conditions.

Taken together, these results suggest a mechanistic model for the A1AR-A2aAR heterodimerization-mediated regulation of EAAT2 expression and glutamate uptake through YY1-induced recruitment of HDAC1 to the PPARγ promoter region. In this model, OGD promotes A1AR-A2aAR heterodimer formation. This complex elevates YY1 protein levels, represses EAAT2 expression, and impairs the uptake of glutamate by astrocytes. These effects can be partly reversed by the activation of A1AR or the inactivation of A2aAR. Additionally, YY1 suppresses the expression of EAAT2 through the recruitment of HDAC1 to the PPARγ promoter region (Figure 6). These findings give insight into the mechanism by which multiple ARs regulate EAAT2 and should facilitate the development of therapeutics for ischemic stroke.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions
Li Gui and Xianhua Hou designed the study and the experiments. Xianhua Hou, Yuan Li, and Yuanyuan Huang were responsible for the data collection. Xianhua Hou and Huan Zhao analyzed the data. Xianhua Hou drafted the manuscript. Xianhua Hou and Li Gui revised the manuscript and all authors approved the final manuscript.

Acknowledgments
This work was supported by the National Science Foundation of China (NSFC, # 81371274) to L.G. and the National Science Foundation of China (NSFC, # 81601025) and the Military Medical Science and Technology Innovation Program (SWH2017YBXM-15) to X.H. We thank the American Journal Experts (http://www.aje.cn/) for linguistic assistance during the preparation of this manuscript.

Supplementary Materials
The supplement file showed the information on materials and reagents, including brand and lot numbers. (Supplementary Materials)

References
[1] L. Liu, D. Wang, K. S. Wong, and Y. Wang, "Stroke and stroke care in China: huge burden, significant workload, and a national priority," Stroke, vol. 42, no. 12, pp. 3651–3654, 2011.
[2] Y. Wang, Z. Li, X. Zhao et al., "Stroke care quality in China: substantial improvement, and a huge challenge and
opportunity," *International Journal of Stroke*, vol. 12, no. 3, pp. 229–235, 2016.

[3] P. Karki, P. Hong, J. Johnson Jr. et al., "Arundic acid increases expression and function of astrocytic glutamate transporter EAAT1 via the ERK, Akt, and NF-κB pathways," *Molecular Neurobiology*, vol. 55, no. 6, pp. 5031–5046, 2018.

[4] A. H. Cornell-Bell, P. G. Thomas, and S. J. Smith, "The excitatory neurotransmitter glutamate causes filopodia formation in cultured hippocampal astrocytes," *Glia*, vol. 3, no. 5, pp. 322–334, 1990.

[5] N. Zhao, X. Xu, Y. Jiang et al., "Lipocalin-2 may produce damaging effect after cerebral ischemia by inducing astrocytes classical activation," *Journal of Neuroinflammation*, vol. 16, no. 1, 2019.

[6] G. J. Zipfèl, D. J. Babcock, J. M. Lee, and D. W. Choi, "Neuronal apoptosis after CNS injury: the roles of glutamate and calcium," *Journal of Neurotrauma*, vol. 17, no. 10, pp. 857–869, 2000.

[7] U. Dinnagi, C. Iadecola, and M. A. Moskowitz, "Pathobiology of ischaemic stroke: an integrated view," *Trends in Neurosciences*, vol. 22, no. 9, pp. 391–397, 1999.

[8] S. A. Liddelow and B. A. Barres, "Reactive astrocytes: production, function, and therapeutic potential," *Immunity*, vol. 46, no. 6, pp. 957–967, 2017.

[9] Z. Liu and M. Chopp, "Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke," *Progress in Neurobiology*, vol. 144, pp. 103–120, 2016.

[10] E. Pajarillo, A. Rizor, J. Lee, M. Aschner, and E. Lee, "The role of astroglial glutamate transporters GLT-1 and GLAST in neurological disorders: potential targets for neurotherapeutics," *Neuropharmacology*, vol. 161, article 107559, 2019.

[11] S. Mahmoud, M. Gharaogloo, C. Simard, and D. Gris, "Astrocytes maintain glutamate homeostasis in the CNS by controlling the balance between glutamate uptake and release," *Cells*, vol. 8, no. 2, p. 184, 2019.

[12] C. B. Divito and S. M. Underhill, "Excitatory amino acid transporters: roles in glutamatergic neurotransmission," *Neurochemistry International*, vol. 73, pp. 172–180, 2014.

[13] T. Storck, S. Schulte, K. Hofmann, and W. Stoffel, "Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 89, no. 22, pp. 10955–10959, 1992.

[14] K. P. Lehre, L. M. Levy, O. P. Ottersen, J. Storm-Mathisen, and N. C. Danbolt, "Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations," *The Journal of Neuroscience*, vol. 15, 3 Part 1, pp. 1835–1853, 1995.

[15] K. Tanaka, K. Watase, T. Manabe et al., "Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1," *Science*, vol. 276, no. 5319, pp. 1699–1702, 1997.

[16] L. N. Chernyshева, E. D. Maiburd, and L. S. Tambulatova, "Physical and psychological tolerance of patients with Hodgkin's disease," *Terapevticheskii Arkhiv*, vol. 55, no. 9, pp. 134–136, 1983.

[17] M. B. Robinson, "The family of sodium-dependent glutamate transporters: a focus on the GLT-1/EAAT2 subtype," *Neurochemistry International*, vol. 33, no. 6, pp. 479–491, 1998.

[18] P. Karki, A. Webb, A. Zerguine, J. Choi, D. S. Son, and E. Lee, "Mechanism of raloxifene-induced upregulation of glutamate transporters in rat primary astrocytes," *Glia*, vol. 62, no. 8, pp. 1270–1283, 2014.

[19] J. M. Decker, L. Krüger, A. Sydow et al., "The Tau/A152T mutation, a risk factor for frontotemporal-spectrum disorders, leads to NR2B receptor-mediated excitotoxicity," *EMBO Reports*, vol. 17, no. 4, pp. 552–569, 2016.

[20] V. Lutgen, S. D. Narasipura, A. Sharma, S. Min, and L. Al-Harthi, "β-catenin signaling positively regulates glutamate uptake and metabolism in astrocytes," *Journal of Neuroinflammation*, vol. 13, no. 1, p. 242, 2016.

[21] P. Karki, A. Webb, K. Smith et al., "Yin Yang 1 is a repressor of glutamate transporter EAAT2, and it mediates manganese-induced decrease of EAAT2 expression in astrocytes," *Molecular and Cellular Biology*, vol. 34, no. 7, pp. 1280–1289, 2014.

[22] M. Lazarus, Y. Oishi, T. E. Bjorness, and R. W. Greene, "Gating and the need for sleep: dissociable effects of adenosine A1 and A2A receptors," *Frontiers in Neuroscience*, vol. 13, p. 740, 2019.

[23] J. W. Daly, P. Butts-Lamb, and W. Padgett, "Subclasses of adenosine receptors in the central nervous system: interaction with caffeine and related methylxanthines," *Cellular and Molecular Neurobiology*, vol. 3, no. 1, pp. 69–80, 1983.

[24] A. K. Dixon, A. K. Gubitz, D. I. Sirinathsinghji, P. J. Richardson, and T. C. Freeman, "Tissue distribution of adenosine receptor mRNAs in the rat," *British Journal of Pharmacology*, vol. 118, no. 6, pp. 1461–1468, 1996.

[25] B. B. Fredholm, A. P. Ijzerman, K. A. Jacobson, J. Linden, and C. E. Müller, "International union of basic and clinical pharmacology. LXXXI. nomenclature and classification of adenosine receptors—an update," *Pharmacological Reviews*, vol. 63, no. 1, pp. 1–34, 2011.

[26] J. Fastbom and B. B. Fredholm, "Inhibition of [3H]glutamate release from rat hippocampal slices by L-phenylisopropyladenosine," *Acta Physiologica Scandinavica*, vol. 125, no. 1, pp. 121–123, 1985.

[27] F. Ciruela, V. Casadó, R. J. Rodrigues et al., "Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1/A2A receptor heteromers," *The Journal of Neuroscience*, vol. 26, no. 7, pp. 2080–2087, 2006.

[28] E. M. O’Kane and T. W. Stone, "Interaction between adenosine A1 and A2 receptor-mediated responses in the rat hippocampus in vitro," *European Journal of Pharmacology*, vol. 362, no. 1, pp. 17–25, 1998.

[29] S. Ferre, F. Ciruela, J. Borycz et al., "Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain," *Frontiers in Bioscience*, vol. 13, pp. 2391–2399, 2008.

[30] S. Cristovão-Ferreira, G. Navarro, M. Brugarolas et al., "A1R–A2AR heteromers coupled to Gs and Go proteins modulate GABA transport into astrocytes," *Purinergic Signal*, vol. 9, no. 3, pp. 433–449, 2013.

[31] L. V. Lopes, R. A. Cunha, and J. A. Ribeiro, "Cross talk between A1 and A2a, adenosine receptors in the hippocampus and cortex of young adult and old rats," *Journal of Neurophysiology*, vol. 82, no. 6, pp. 3196–3203, 1999.

[32] J. F. Chen, P. K. Sonsalla, P. Pedata et al., "Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulations," *Progress in Neurobiology*, vol. 83, no. 5, pp. 310–331, 2007.

[33] W. Li, S. Dai, J. An et al., "Genetic inactivation of adenosine A2A receptors attenuates acute traumatic brain injury in the..."
mouse cortical impact model,” *Experimental Neurology*, vol. 215, no. 1, pp. 69–76, 2009.

[34] J. A. Ribeiro, A. M. Sebastiao, and A. de Mendonca, “Adenosine receptors in the nervous system: pathophysiological implications,” *Progress in Neurobiology*, vol. 68, no. 6, pp. 377–392, 2002.

[35] R. Riccicarello, I. D’Alimonte, P. Ballerini et al., “Molecular signaling mediating the protective effect of A1 adenosine and mGlu3 metabotropic glutamate receptor activation against apoptosis by oxygen/glucose deprivation in cultured astrocytes,” *Molecular Pharmacology*, vol. 71, no. 5, pp. 1369–1380, 2007.

[36] A. M. Zhou, W. B. Li, Q. J. Li, H. Q. Liu, R. F. Feng, and H. G. Zhao, “A short cerebral ischemic preconditioning up-regulates adenosine receptors in the hippocampal CA1 region of rats,” *Neuroscience Research*, vol. 48, no. 4, pp. 397–404, 2004.

[37] T. V. Dunwiddie and S. A. Masino, “The role and regulation of adenosine in the central nervous system,” *Annual Review of Neuroscience*, vol. 24, pp. 31–55, 2001.

[38] S. Schilide, C. Bohrer, K. Beck, and C. Schachtrup, “Isolation and culture of mouse cortical astrocytes,” *Journal of Visualized Experiments*, no. 71, article e50079, 2013.

[39] D. Qian, L. Li, Y. Rong et al., “Blocking Notch signal pathway suppresses the activation of neurotrophic A1 astrocytes after spinal cord injury,” *Cell Cycle*, vol. 18, no. 21, pp. 3010–3029, 2019.

[40] S. Duan, C. M. Anderson, B. A. Stein, and R. A. Swanson, “Glutamate induces rapid upregulation of astrocyte glutamate transport and cell-surface expression of GLAST,” *The Journal of Neuroscience*, vol. 19, no. 23, pp. 10193–10200, 1999.

[41] W. Bai, P. Li, Y. L. Ning et al., “Adenosine A2A receptor inhibition restores the normal transport of endothelial glutamate transporters in the brain,” *Biochemical and Biophysical Research Communications*, vol. 498, no. 4, pp. 795–802, 2018.

[42] Y. J. Day, L. Huang, H. Ye, J. Linden, and M. D. Okusa, “Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages,” *American Journal of Physiology-Renal Physiology*, vol. 288, no. 4, pp. F722–F731, 2005.

[43] C. Romera, O. Hurtado, J. Mallol et al., “Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARγ target gene involved in neuroprotection,” *Journal of Cerebral Blood Flow and Metabolism*, vol. 27, no. 7, pp. 1327–1338, 2007.

[44] P. H. Lai, W. L. Wang, C. Y. Ko et al., “HDAC1/HDAC3 modulates PPARγ2 transcription through the sumoylated CEBPD in hepatic lipogenesis,” *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research*, vol. 1783, no. 10, pp. 1803–1814, 2008.

[45] J. P. Vilardaga, L. F. Agnati, K. Fuxe, and F. Ciruela, “G-protein-coupled receptor heteromer dynamics,” *Journal of Cell Science*, vol. 123, Part 24, pp. 4215–4220, 2010.

[46] M. Chabre, P. Deterre, and B. Antonny, “The apparent cooperativity of some GPCRs does not necessarily imply dimerization,” *Trends in Pharmacological Sciences*, vol. 30, no. 4, pp. 182–187, 2009.

[47] W. Guo, E. Urizar, M. Krailikova et al., “Dopamine D2 receptors form higher order oligomers at physiological expression levels,” *The EMBO Journal*, vol. 27, no. 17, pp. 2293–2304, 2008.

[48] G. Milligan, “G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function,” *British Journal of Pharmacology*, vol. 158, no. 1, pp. 5–14, 2009.

[49] S. Terrillon and M. Bouvier, “Roles of G-protein-coupled receptor dimerization,” *EMBO Reports*, vol. 5, no. 1, pp. 30–34, 2004.

[50] S. C. Prinster, C. Hauge, and R. A. Hall, “Heterodimerization of g protein-coupled receptors: specificity and functional significance,” *Pharmacological Reviews*, vol. 57, no. 3, pp. 289–298, 2005.

[51] S. Ferré, F. Ciruela, C. Quiroz et al., “Adenosine receptor heteromers and their integrative role in striatal function,” *ScientificWorldJournal*, vol. 7, article 829039, pp. 74–85, 2007.

[52] J. Wu, M. R. Lee, T. Kim et al., “Regulation of ethanol-sensitive EAAT2 expression through adenosine A1 receptor in astrocytes,” *Biochemical and Biophysical Research Communications*, vol. 406, no. 1, pp. 47–52, 2011.

[53] J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” *Annual Review of Medicine*, vol. 53, pp. 409–435, 2002.

[54] L. Szeles, D. Torocsik, and L. Nagy, “PPARγ in immunity and inflammation: cell types and diseases,” *Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids*, vol. 1771, no. 8, pp. 1014–1030, 2007.

[55] M. Ahmadian, J. M. Suh, N. Hah et al., “PPARγ signaling and metabolism: the good, the bad and the future,” *Nature Medicine*, vol. 19, no. 5, pp. 557–566, 2013.

[56] K. Tureyen, R. Kapadia, K. K. Bowen et al., “Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents,” *Journal of Neurochemistry*, vol. 101, no. 1, pp. 41–56, 2007.

[57] J. Ching, S. Amiridis, S. S. Styli et al., “The peroxisome proliferator-activated receptor gamma agonist pioglitazone increases functional expression of the glutamate transporter excitatory amino acid transporter 2 (EAAT2) in human glioblastoma cells,” *Oncotarget*, vol. 6, no. 25, pp. 21301–21314, 2015.

[58] Z. Deng, P. Cao, M. M. Wan, and G. Sui, “Yin Yang 1: a multifaceted protein beyond a transcription factor,” *Transcription*, vol. 1, no. 2, pp. 81–84, 2010.

[59] S. Gordon, G. Akopyan, H. Garban, and B. Bonavida, “Transcription factor YY1: structure, function, and therapeutic implications in cancer biology,” *Oncogene*, vol. 25, no. 8, pp. 1125–1142, 2006.

[60] F. H. Wilkinson, K. Park, and M. L. Atchison, “Polycomb recruitment to DNA in vivo by the YY1 REPO domain,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 51, pp. 19296–19301, 2006.

[61] M. Wan, W. Huang, T. E. Kute et al., “Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27,” *The American Journal of Pathology*, vol. 180, no. 5, pp. 2120–2133, 2012.

[62] D. Chinnappan, D. Xiao, A. Ratnasari, C. Andry, T. C. King, and H. C. Weber, “Transcription factor YY1 expression in human gastrointestinal cancer cells,” *International Journal of Oncology*, vol. 34, no. 5, pp. 1417–1423, 2009.

[63] J. Zan, H. Zhang, A. P. Gu et al., “Yin Yang 1 dynamically regulates antiviral innate immune responses during viral infection,” *Cellular Physiology and Biochemistry*, vol. 44, no. 2, pp. 607–617, 2017.
[64] Y. He and P. Casaccia-Bonnefil, “The Yin and Yang of YY1 in the nervous system,” Journal of Neurochemistry, vol. 106, no. 4, pp. 1493–1502, 2008.

[65] S. Rosas, M. A. Vargas, E. Lopez-Bayghen, and A. Ortega, “Glutamate-dependent transcriptional regulation of GLAST/EAAT1: a role for YY1,” Journal of Neurochemistry, vol. 101, no. 4, pp. 1134–1144, 2007.

[66] G. Aguirre, S. Rosas, E. Lopez-Bayghen, and A. Ortega, “Valproate-dependent transcriptional regulation of GLAST/EAAT1 expression: involvement of Ying-Yang 1,” Neurochemistry International, vol. 52, no. 7, pp. 1322–1331, 2008.

[67] P. Karki, C. Kim, K. Smith, D. S. Son, M. Aschner, and E. Lee, “Transcriptional regulation of the astrocytic excitatory amino acid transporter 1 (EAAT1) via NF-κB and Yin Yang 1 (YY1),” The Journal of Biological Chemistry, vol. 290, no. 39, pp. 23725–23737, 2015.

[68] Q. Zhang, D. B. Stovall, K. Inoue, and G. Sui, “The oncogenic role of Yin Yang 1,” Critical Reviews in Oncogenesis, vol. 16, no. 3-4, pp. 163–197, 2011.

[69] W. M. Yang, C. Inouye, Y. Zeng, D. Bearss, and E. Seto, “Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 12845–12850, 1996.

[70] M. Joo, J. G. Wright, N. N. Hu et al., “Yin Yang 1 enhances cyclooxygenase-2 gene expression in macrophages,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 292, no. 5, pp. L1219–L1226, 2007.